OptimizeRx Corporation (OPRX) Key Metrics
OPRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $160.1M
- Enterprise value
- $138.5M
- P/E (TTM)
- 35.4
- Forward P/E
- 5.6
- PEG ratio
- 1.61
- Price / sales
- 1.6 10-yr median 4.3
- Price / book
- 1.1 10-yr median 3.1
- EV / EBITDA
- 8.8 10-yr median 265.4
- Dividend yield
- —
- Beta
- 1.26
OPRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsOPRX valuation Price multiples at each fiscal year-end price.
OPRX returns How much profit the business earns on the capital it uses.
OPRX per-share figures Results divided by the shares outstanding at year-end.
OPRX financial health Debt, liquidity and how easily interest is covered.
OPRX efficiency & capital use Working capital cycle and where the cash goes.
OPRX valuation history
OPRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OPRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OPRX cash returned to shareholders
OPRX price vs earnings per share
OPRX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $232.9M | $88.9M | $245.1M | $298.8M | $1.10B | $462.0M | $137.5M | $130.1M | $46.3M | $24.1M |
| Enterprise value | $235.7M | $108.7M | $268.0M | $224.9M | $1.01B | $452.0M | $119.2M | $121.2M | $42.3M | $19.5M |
| P/E ratio | 45.4 | — | — | — | — | — | — | 575.0 | — | — |
| Price / sales | 2.1 | 1.0 | 3.4 | 4.8 | 17.9 | 10.7 | 5.6 | 6.1 | 3.8 | 3.1 |
| Price / book | 1.8 | 0.8 | 1.9 | 2.4 | 8.4 | 9.2 | 3.1 | 7.1 | 7.4 | 3.1 |
| Price / free cash flow | 12.5 | 18.6 | — | 28.7 | — | — | — | 185.5 | — | — |
| Price / operating cash flow | 12.4 | 18.2 | — | 28.0 | — | — | — | 164.2 | — | — |
| EV / sales | 2.2 | 1.2 | 3.7 | 3.6 | 16.6 | 10.4 | 4.8 | 5.7 | 3.5 | 2.5 |
| EV / EBITDA | 14.2 | — | — | — | 432.9 | 601.3 | — | 98.0 | — | — |
| EV / free cash flow | 12.6 | 22.8 | — | 21.6 | — | — | — | 172.8 | — | — |
| Earnings yield | 2.2% | −22.6% | −7.2% | −3.8% | 0.0% | −0.5% | −2.3% | 0.2% | −4.5% | −6.4% |
| Free cash flow yield | 8.0% | 5.4% | −3.3% | 3.5% | 0.0% | −1.4% | −2.4% | 0.5% | −3.3% | −3.4% |
| Dividend yield | — | — | — | 0.0% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 1.0% | 3.1% | 6.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 3.4% |
| Share price at fiscal year-end | $12.26 | $4.86 | $14.31 | $16.80 | $62.11 | $31.16 | $10.27 | $10.97 | $4.71 | $2.43 |
| Per share | ||||||||||
| Revenue per share | $5.76 | $5.04 | $4.18 | $3.51 | $3.46 | $2.92 | $1.84 | $1.79 | $1.24 | $0.78 |
| Earnings per share | $0.27 | −$1.10 | −$1.03 | −$0.64 | $0.02 | −$0.15 | −$0.23 | $0.02 | −$0.21 | −$0.16 |
| Operating cash flow per share | $0.99 | $0.27 | −$0.42 | $0.60 | $0.04 | −$0.43 | −$0.12 | $0.07 | −$0.15 | −$0.05 |
| Free cash flow per share | $0.98 | $0.26 | −$0.47 | $0.59 | $0.01 | −$0.43 | −$0.24 | $0.06 | −$0.16 | −$0.08 |
| Cash per share | $1.23 | $0.73 | $0.81 | $4.17 | $4.79 | $0.71 | $1.41 | $0.75 | $0.52 | $0.71 |
| Book value per share | $6.75 | $6.40 | $7.39 | $7.09 | $7.43 | $3.37 | $3.35 | $1.56 | $0.63 | $0.79 |
| Tangible book value per share | $0.88 | $0.03 | −$0.07 | $5.08 | $5.99 | $1.56 | $1.21 | $0.80 | $0.47 | $0.56 |
| Dividends per share | — | — | — | $0.00 | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.01 | $0.05 | $0.01 | $0.03 | $0.01 | $0.12 | $0.01 | $0.00 | $0.04 |
| Debt per share | $1.37 | $1.81 | $2.15 | $0.01 | $0.02 | $0.03 | $0.04 | — | $0.12 | $0.25 |
| Shares outstanding | 19.0M | 18.3M | 17.1M | 17.8M | 17.7M | 14.8M | 13.4M | 11.9M | 9.8M | 9.9M |
| Change in shares outstanding | +3.9% | +6.8% | −3.7% | +0.5% | +19.3% | +10.8% | +12.9% | +20.8% | −0.8% | +20.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 4.2% | −16.5% | −13.9% | −8.9% | 0.4% | −4.7% | −9.9% | 1.8% | −30.0% | −18.4% |
| Return on invested capital (ROIC) | 6.7% | −7.6% | −20.7% | −19.6% | 0.6% | −5.1% | −16.2% | 2.4% | −60.7% | −39.3% |
| Return on assets (ROA) | 2.9% | −11.3% | −11.0% | −8.3% | 0.4% | −3.8% | −7.7% | 1.3% | −19.8% | −12.9% |
| Return on tangible assets | 7.9% | −36.7% | −31.6% | −11.6% | 0.3% | −6.6% | −11.2% | 1.4% | −25.7% | −16.7% |
| Free cash flow margin | 17.0% | 5.2% | −11.3% | 16.7% | 0.4% | −14.9% | −13.2% | 3.3% | −12.6% | −10.5% |
| Income quality (OCF / net income) | 3.65 | — | — | — | 1.92 | — | — | 3.50 | — | — |
| Financial health | ||||||||||
| Total debt | $26.1M | $33.2M | $36.8M | $234,434 | $327,708 | $448,753 | $564,184 | — | $1.2M | $2.5M |
| Cash & short-term investments | $23.4M | $13.4M | $13.9M | $74.1M | $84.7M | $10.5M | $18.9M | $8.9M | $5.1M | $7.0M |
| Net debt | $2.7M | $19.8M | $23.0M | −$73.9M | −$84.4M | −$10.1M | −$18.3M | −$8.9M | −$3.9M | −$4.5M |
| Debt / equity | 0.20 | 0.28 | 0.29 | 0.00 | 0.00 | 0.01 | 0.01 | — | 0.19 | 0.32 |
| Debt / assets | 0.15 | 0.19 | 0.20 | 0.00 | 0.00 | 0.01 | 0.01 | — | 0.12 | 0.22 |
| Net debt / EBITDA | 0.17 | — | — | — | −36.00 | −13.39 | — | −7.21 | — | — |
| Current ratio | 3.04 | 2.89 | 3.04 | 11.74 | 12.29 | 3.28 | 4.44 | 3.77 | 2.49 | 2.78 |
| Quick ratio | 3.04 | 2.89 | 3.04 | 11.53 | — | 3.28 | 4.44 | 3.77 | 2.49 | 2.78 |
| Interest coverage | 2.3 | -2.2 | -18.2 | -14.4 | 3.0 | -31.1 | -3.8 | — | — | — |
| Working capital | $43.5M | $35.3M | $36.4M | $90.2M | $105.7M | $22.8M | $21.0M | $11.7M | $5.3M | $6.5M |
| Invested capital | $131.0M | $136.8M | $149.5M | $52.2M | $47.0M | $39.9M | $26.6M | $9.5M | $2.3M | $3.3M |
| Tangible asset value | $16.6M | $613,000 | −$1.2M | $90.4M | $106.0M | $23.1M | $16.2M | $9.5M | $4.7M | $5.6M |
| Net current asset value | $16.1M | −$199,000 | −$2.5M | $90.0M | $105.5M | $22.5M | $15.4M | $9.4M | $5.3M | $6.5M |
| Graham number | $6.41 | — | — | — | $1.89 | — | — | $0.82 | — | — |
| Graham net-net per share | $0.19 | −$0.66 | −$0.88 | $4.67 | −$159,138.11 | $0.92 | $0.94 | $0.60 | $0.42 | $0.57 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $226 | — | — | — | — | — | — |
| Share buybacks (net) | — | $911,000 | $7.5M | $20.0M | $0 | $0 | $0 | $0 | $390,000 | $806,915 |
| Dividends + buybacks / free cash flow | — | 19.1% | — | 192.4% | 0.0% | — | — | 0.0% | — | — |
| Capex / revenue | 0.1% | 0.1% | 1.2% | 0.4% | 0.8% | 0.3% | 6.5% | 0.4% | 0.3% | 4.5% |
| Capex / operating cash flow | 0.3% | 2.3% | — | 2.3% | 66.9% | — | — | 11.5% | — | — |
| Capex / depreciation | 0.01 | 0.03 | 0.36 | 0.12 | 0.25 | 0.06 | 1.24 | 0.29 | 0.13 | 1.49 |
| Stock-based compensation / revenue | 6.4% | 12.4% | 19.2% | 25.2% | 9.0% | 7.3% | 9.2% | 8.8% | 0.7% | 2.3% |
| R&D / revenue | — | — | — | — | — | 2.5% | 6.5% | 3.2% | 8.3% | 5.1% |
| SG&A / revenue | 45.9% | 66.5% | 87.1% | 78.8% | 54.2% | 46.0% | 58.4% | 48.5% | 55.7% | 67.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 127.9 | 149.6 | 151.7 | 137.2 | 127.1 | 106.6 | 102.9 | 85.1 | 97.7 | 139.1 |
| Days of inventory on hand | — | — | — | -43,758,398.7 | -80,110,558.1 | — | — | — | 0.0 | — |
| Days payables outstanding | 17.2 | 24.4 | 24.1 | 16.8 | 8.7 | 10.6 | 18.0 | 17.6 | 24.4 | 187.6 |
| Cash conversion cycle (days) | 110.7 | 125.1 | 127.6 | -43,758,278.3 | -80,110,439.7 | 96.1 | 84.9 | 67.5 | 73.3 | -48.5 |
| Receivables turnover | 2.85 | 2.44 | 2.41 | 2.66 | 2.87 | 3.42 | 3.55 | 4.29 | 3.74 | 2.62 |
| Payables turnover | 21.18 | 14.94 | 15.16 | 21.78 | 41.88 | 34.57 | 20.26 | 20.73 | 14.94 | 1.95 |
| Inventory turnover | — | — | — | — | — | — | — | — | 6,174,614.00 | — |
| Asset turnover | 0.63 | 0.52 | 0.45 | 0.45 | 0.61 | 0.74 | 0.60 | 1.22 | 1.14 | 0.65 |
| Average receivables | $38.4M | $37.8M | $29.7M | $23.5M | $21.3M | $12.7M | $6.9M | $4.9M | $3.2M | $3.0M |
| Average payables | $1.9M | $2.2M | $1.9M | $1.1M | $612,529 | $555,622 | $452,002 | $434,150 | $413,252 | $1.8M |
| Average inventory | — | — | — | −$2.82T | −$5.63T | — | — | — | $1 | — |
| Intangibles / total assets | 63.1% | 68.0% | 69.7% | 26.5% | 18.0% | 44.5% | 50.6% | 35.7% | 16.0% | 19.6% |
Computed from OPRX's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OPRX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), OptimizeRx traded at 45.4 times earnings. Based on the latest twelve months, the trailing P/E is 35.4 and the forward P/E is 5.6. OptimizeRx earned a return on equity of 4.2% and a return on invested capital of 6.7% in fiscal 2025. It ended the year with $26.1 million of debt and $23.4 million in cash and short-term investments, net debt of $2.7 million. The share count rose 91.9% from 9.9M to 19.0M over 9 years.
See the OPRX income statement, the OPRX chart for price history, or the OPRX stock overview for the latest quote and news.
OPRX key metrics FAQ
What is OptimizeRx's P/E ratio?
OptimizeRx's trailing P/E ratio is 35.4 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 5.6. At the end of fiscal 2025 it was 45.4.
What is OptimizeRx's EV/EBITDA?
OptimizeRx's enterprise value was 14.2 times EBITDA at the end of fiscal 2025 (enterprise value $235.7 million, EBITDA $16.6 million); the current EV/EBITDA is 8.8.
What is OptimizeRx's return on equity?
OptimizeRx's return on equity (ROE) was 4.2% in fiscal 2025: net income of $5.1 million on average shareholders' equity of $122.6 million.
What is OptimizeRx's ROIC?
OptimizeRx's return on invested capital was 6.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does OptimizeRx have?
OptimizeRx had total debt of $26.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.20 and $2.7 million of net debt (0.17 times EBITDA).
What is OptimizeRx's free cash flow yield?
OptimizeRx generated $18.7 million of free cash flow in fiscal 2025, a free cash flow yield of 8.0% on its market value at year-end ($232.9 million).
What is OptimizeRx's current ratio?
OptimizeRx's current ratio was 3.04 at the end of fiscal 2025: current assets were 3.04 times current liabilities.